TY - JOUR
T1 - Direct costs of acute recurrent and chronic pancreatitis in children in the INSPPIRE registry
AU - Ting, Jie
AU - Wilson, Leslie
AU - Schwarzenberg, Sarah Jane
AU - Himes, Ryan
AU - Barth, Bradley
AU - Bellin, Melena D.
AU - Durie, Peter R.
AU - Fishman, Douglas S.
AU - Freedman, Steven D.
AU - Gariepy, Cheryl E.
AU - Giefer, Matthew J.
AU - Gonska, Tanja
AU - Husain, Sohail Z.
AU - Kumar, Soma
AU - Morinville, Veronique D.
AU - Lowe, Mark E.
AU - Ooi, Chee Y.
AU - Pohl, John F.
AU - Troendle, David
AU - Usatin, Danielle
AU - Werlin, Steven L.
AU - Wilschanski, Michael
AU - Heyman, Melvin B.
AU - Uc, Aliye
N1 - Publisher Copyright:
© 2016 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.
PY - 2016
Y1 - 2016
N2 - Objective: To estimate selected direct medical care costs of children with chronic pancreatitis (CP) and acute recurrent pancreatitis (ARP). Methods: We performed a cross-sectional study of data from International Study Group of Pediatric Pancreatitis: In Search for a Cure (INSPPIRE), a multinational registry of children with ARP or CP. We determined health care utilization and estimated costs of hospitalizations, surgical and endoscopic procedures, and medications in our study population. Health care utilization data were obtained from all subjects enrolled in the study, and costs were calculated using national United States costs. Results: We included 224 subjects (median age 12.7 years), 42% of whomhad CP. Mean number of hospitalizations, including for surgery and endoscopic retrograde cholangiopancreatography, was 2.3 per person per year, costing an estimated average $38,755 per person per year. Including outpatient medications, estimated total mean cost was $40,589 per person per year. Subjects using surgical procedures or endoscopic retrograde cholangiopancreatography incurred mean annual costs of $42,951 per person and $12,035 per person, respectively. Estimated annual costs of pancreatic enzyme replacement therapy, diabetic medications, and painmedicationswere $4114, $1761, and $614 per person, respectively. In an exploratory analysis, patients with the following characteristics appear to accrue higher costs than those without them: more frequent ARP attacks per year, reported constant or episodic pain, family history of pancreatic cancer, and use of pain medication. Conclusions: ARP and CP are uncommon childhood conditions. The severe burden of disease associated with these conditions and their chronicity results in high health care utilization and costs. Interventions that reduce the need for hospitalization could lower costs for these children and their families.
AB - Objective: To estimate selected direct medical care costs of children with chronic pancreatitis (CP) and acute recurrent pancreatitis (ARP). Methods: We performed a cross-sectional study of data from International Study Group of Pediatric Pancreatitis: In Search for a Cure (INSPPIRE), a multinational registry of children with ARP or CP. We determined health care utilization and estimated costs of hospitalizations, surgical and endoscopic procedures, and medications in our study population. Health care utilization data were obtained from all subjects enrolled in the study, and costs were calculated using national United States costs. Results: We included 224 subjects (median age 12.7 years), 42% of whomhad CP. Mean number of hospitalizations, including for surgery and endoscopic retrograde cholangiopancreatography, was 2.3 per person per year, costing an estimated average $38,755 per person per year. Including outpatient medications, estimated total mean cost was $40,589 per person per year. Subjects using surgical procedures or endoscopic retrograde cholangiopancreatography incurred mean annual costs of $42,951 per person and $12,035 per person, respectively. Estimated annual costs of pancreatic enzyme replacement therapy, diabetic medications, and painmedicationswere $4114, $1761, and $614 per person, respectively. In an exploratory analysis, patients with the following characteristics appear to accrue higher costs than those without them: more frequent ARP attacks per year, reported constant or episodic pain, family history of pancreatic cancer, and use of pain medication. Conclusions: ARP and CP are uncommon childhood conditions. The severe burden of disease associated with these conditions and their chronicity results in high health care utilization and costs. Interventions that reduce the need for hospitalization could lower costs for these children and their families.
KW - Economic
KW - Health care costs
KW - Hospitalization
KW - Pain
KW - Quality of life
UR - http://www.scopus.com/inward/record.url?scp=84959894704&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959894704&partnerID=8YFLogxK
U2 - 10.1097/MPG.0000000000001057
DO - 10.1097/MPG.0000000000001057
M3 - Article
C2 - 26704866
AN - SCOPUS:84959894704
SN - 0277-2116
VL - 62
SP - 443
EP - 449
JO - Journal of pediatric gastroenterology and nutrition
JF - Journal of pediatric gastroenterology and nutrition
IS - 3
ER -